Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Jun;4(6):1083-8.
doi: 10.2215/CJN.06041108. Epub 2009 May 28.

Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients

Alfons Segarra  1 , Manuel Praga, Natalia Ramos, Natalia Polanco, Isabel Cargol, Elena Gutierrez-Solis, M Rosa Gomez, Bruno Montoro, Joaquim Camps
Affiliations
Clinical Trial

Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients

Alfons Segarra et al. Clin J Am Soc Nephrol. 2009 Jun.

Abstract

Background and objectives: Calcineurin inhibitors (CNIs) induce remission of proteinuria in most nephrotic patients with membranous glomerulonephropathy (MGN). However, 60% of patients become treatment dependent and are at risk of chronic nephrotoxicity. The aim of this study was to evaluate the efficacy of rituximab in patients with long-term dependence on CNIs.

Design, setting, participants, and measurements: Thirteen patients with MGN, normal renal function, and proven dependence on CNIs, despite previous treatment with other immunosuppressant drugs, received a single trial of four weekly doses of rituximab (375 mg/m(2)). Outcome measures were the percentage of patients with CNI withdrawal and no evidence of relapse and the percentage of patients with complete or partial remission 30 mo after CNI withdrawal.

Results: After rituximab, proteinuria decreased significantly (2.5 +/- 0,76 basal versus 0.85 +/- 0.17 at 6 mo; P = .0003). CNIs and other immunosuppressant drugs could be withdrawn in all patients with no evidence of relapse. After CNI withdrawal, GFR increased significantly (90.3 +/- 15 basal to 106.4 +/- 20 at 3 mo with a mean increase of 15.3% [range 0-20]). Three patients suffered a relapse of nephrotic proteinuria 19, 23, and 28 mo after rituximab treatment; all were successfully treated with a second course of rituximab. At 30 mo, all patients were in remission.

Conclusions: In patients with MGN with long-term CNI dependence, rituximab can be an effective tool to overcome dependence on CNI, thus avoiding the risk of nephrotoxicity related to the chronic exposure to these drugs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Evolution of CD-19+ cell count over the total observation period. Basal: CD-19+ cell counts before rituximab administration. Values within 15 and 30 mo exclude CD-19 counts of the three patients who suffered a relapse and needed retreatment.
Figure 2.
Figure 2.
Time course of urinary protein excretion (g/24 h) in individual patients from entry into the study (basal) to end of follow-up (month 30) Values represent proteinuria in g/d
See this image and copyright information in PMC

Comment in

References

    1. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960–966, 1992 - PubMed
    1. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901–907, 1997 - PubMed
    1. Wu Q, Jinde K, Nishina M, Tanabe R, Endoh M, Okada Y, Sakai H, Kurokawa K: Analysis of prognostic predictors in idiopathic membranous nephropathy. Am J Kidney Dis 37: 380–387, 2001 - PubMed
    1. Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol 23: 324–332, 2003 - PubMed
    1. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47: 1130–1135, 1995 - PubMed

Publication types

MeSH terms